Sona Nanotech Inc (TSE:SONA)
:SONA
Top Page
Sona Nanotech Inc
(SONA)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.32
▼(-21.25% Downside)
Action:ReiteratedDate:04/08/26
The score is driven primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and negative equity). Technicals also weigh on the rating due to a sustained downtrend, while valuation offers limited support because earnings are negative and no dividend yield is available.
Positive Factors
Proprietary gold nanorod technology
Sona’s ownership of proprietary gold nanorod materials is a durable strategic asset: a platform technology can enable multiple diagnostic assays, licensing opportunities, and partnerships. This intellectual-property base supports long-term commercialization options beyond a single product.
Negative Factors
Zero reported revenue
Persistent zero revenue indicates the business has not achieved commercial traction. Without sales, product-market fit and sustainable business economics remain unproven, forcing ongoing reliance on external funding or partnerships to finance operations and delaying any path to self-sustaining cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary gold nanorod technology
Sona’s ownership of proprietary gold nanorod materials is a durable strategic asset: a platform technology can enable multiple diagnostic assays, licensing opportunities, and partnerships. This intellectual-property base supports long-term commercialization options beyond a single product.
Read all positive factors
Sona Nanotech Inc (SONA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$34.31M
Dividend YieldN/A
Average Volume (3M)124.26K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth10.97%
CountryCA
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding114,375,250
10 Day Avg. Volume87,178
30 Day Avg. Volume124,263
Financial Highlights & Ratios
PEG Ratio-2.88
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Sona Nanotech Inc Business Overview & Revenue Model
Company Description
Sona Nanotech Inc., nanotechnology life sciences company, manufactures and sells gold nanorod products for diagnostic tests. The company also provides Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay for the detection of the sp...
How the Company Makes Money
null...
Sona Nanotech Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -720.00K | -733.98K | -457.00K | -60.32K | -65.59K |
| EBITDA | -2.72M | -2.00M | -2.02M | -2.34M | -10.38M |
| Net Income | -3.25M | -2.70M | -2.50M | -2.36M | -10.77M |
Balance Sheet | |||||
| Total Assets | 1.33M | 3.75M | 2.75M | 520.77K | 1.52M |
| Cash, Cash Equivalents and Short-Term Investments | 125.95K | 1.86M | 115.38K | 164.42K | 1.20M |
| Total Debt | 307.74K | 394.67K | 527.68K | 608.47K | 1.34M |
| Total Liabilities | 1.37M | 1.24M | 1.59M | 1.03M | 2.75M |
| Stockholders Equity | -38.78K | 2.51M | 1.16M | -507.86K | -1.22M |
Cash Flow | |||||
| Free Cash Flow | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M |
| Operating Cash Flow | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M |
| Investing Cash Flow | 0.00 | 0.00 | 14.64K | 0.00 | 0.00 |
| Financing Cash Flow | 228.43K | 3.70M | 1.20M | 778.00 | 4.89M |
Sona Nanotech Inc Technical Analysis
Negative
0.40
Price Trends
0.37
Negative
0.43
Negative
0.51
Negative
Market Momentum
-0.02
Negative
42.76
Neutral
35.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.37, and below the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 42.76 is Neutral, neither overbought nor oversold. The STOCH value of 35.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SONA.
Sona Nanotech Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$63.05M | -32.47 | ― | ― | -21.89% | 26.36% | |
48 Neutral | C$58.55M | -498.55 | ― | ― | -9.02% | 14.29% | |
42 Neutral | C$45.61M | -17.24 | ― | ― | -41.70% | -35.42% | |
41 Neutral | C$34.31M | -16.88 | -434.25% | ― | ― | 10.97% |
* Healthcare Sector Average
TSE:SONA
Sona Nanotech Inc
0.30
0.02
7.14%
TSE:BUX
BioMark Diagnostics
0.60
0.35
140.00%
TSE:EBM
Eastwood Bio-Medical Canada
0.85
0.45
112.50%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:MIR
Medmira
0.07
-0.03
-31.58%
TSE:ZYUS
ZYUS Life Sciences
0.56
-0.20
-26.32%
Sona Nanotech Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Sona Nanotech’s Hyperthermia Platform Boosts Immunotherapy Response in Colorectal Cancer Study
Positive
Apr 7, 2026
Sona Nanotech reported peer‑reviewed preclinical results showing its Targeted Hyperthermia Therapy, when combined with a standard PD‑1 inhibitor, produced durable responses in an immunologically cold colorectal cancer model. In animals...
Business Operations and StrategyProduct-Related Announcements
Sona Nanotech to Detail Promising Cancer Therapy Data in Investor Webinar
Positive
Mar 18, 2026
Sona Nanotech will host an investor webinar on March 18 to present follow‑up data from its first‑in‑human study of Targeted Hyperthermia Therapy in ten late‑stage melanoma patients who had failed standard immunotherapy. Led...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.